Clinical trial · Observational
Real-world Studies of CDK4/6 Inhibitors
A Real-world Study on the Treatment of HR+/HER2- Advanced Breast Cancer Patients With CDK4/6 Inhibitors and Treatment Options After Drug Resistance.
NCT07407439CI-TRIAL-00103124recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A single-center, real-world study evaluated the clinical outcomes and safety of CDK4/6 inhibitors combined with endocrine therapy in HR+/HER2- advanced breast cancer, and conducted a summary analysis of the clinical treatment options after the progression of CDK4/6 inhibitors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (5)
- label
- Palbociclib cohort
- description
- Use palbociclib in combination with endocrine therapy as the treatment regimen.
- label
- Abemaciclib cohort
- description
- Use abemaciclib in combination with endocrine therapy as the treatment regimen.
- label
- Ribociclib cohort
- description
- Use ribociclib in combination with endocrine therapy as the treatment regimen.
- label
- Dalcetrapib cohort
- description
- Use dalcetrapib in combination with endocrine therapy as the treatment regimen.
- label
- Other CDK4/6 inhibitors cohort
- description
- Use other CDK4/6 inhibitors in combination with endocrine therapy (including participation in clinical trials of CDK4/6 inhibitors) as the treatment regimen.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age ≥ 18 years old; 2. Patients diagnosed with HR+/HER2- (as defined by the ASCO/CAP guidelines) advanced breast cancer who were treated in our hospital from March 2022 to March 2025; 3. Received CDK4/6 inhibitors (including but not limited to the four currently marketed ones: palbociclib, abemaciclib, ribociclib, and dalpiciclib) as advanced-stage treatment for at least one cycle; 4. Have complete medical history records, including demographic information, pathological reports, treatment records, laboratory test results, and imaging examination reports, etc. Exclusion Criteria: 1. Incomplete medical history data. 2. Only received CDK4/6 inhibitors monotherapy. 3. Received CDK4/6 inhibitors as neoadjuvant/postoperative adjuvant intensification therapy.
References
Publications (0)
Data not yet available
No reference posted for this study.